Effects of sevelamer hydrochloride (Renagel®) and calcium acetate on controlling serum phosphorus in peritonel dialysis patients

被引：0
|
作者：
Evenepoel, Pieter
Selgas, Rafael
Duggal, Ajay
Kelly, Alison
Fan, Stanley L-S.
机构：
[1] Hosp Univ La Paz, Madrid, Spain
[2] Univ Ziekenhuizen, Louvain, Belgium
[3] Genzyme Europe Res, Cambridge, England
[4] Royal London Hosp, Renal Dept, London E1 1BB, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：496 / 496
页数：1
相关论文
共 50 条
  • [1] Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients
    Wilkes, BM
    Reiner, D
    Kern, M
    Burke, S
    CLINICAL NEPHROLOGY, 1998, 50 (06) : 381 - 386
  • [2] Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis
    Evenepoel, Pieter
    Selgas, Rafael
    Caputo, Flavia
    Foggensteiner, Lukas
    Heaf, James G.
    Ortiz, Alberto
    Kelly, Alison
    Chasan-Taber, Scott
    Duggal, Ajay
    Fan, Stanley
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (01) : 278 - 285
  • [3] Control of serum phosphorus in incident hemodialysis patients: A comparison of sevelamer and calcium acetate
    Kessler, Paul
    Bortey, Enoch
    Horwith, Gary
    Rasmussen, Henrik
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 145 - 145
  • [4] Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin
    Kays, MB
    Overholser, BR
    Mueller, BA
    Moe, SM
    Sowinski, KM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (06) : 1253 - 1259
  • [5] Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy
    Ishida, M
    Yao, N
    Yachiku, S
    Anzai, T
    Kobayashi, T
    Ishida, H
    THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 : S16 - S21
  • [6] Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients
    Burke, SK
    Dillon, MA
    Hemken, DE
    Rezabek, MS
    Balwit, JM
    ADVANCES IN RENAL REPLACEMENT THERAPY, 2003, 10 (02): : 133 - 145
  • [7] Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients:: A comparison with calcium acetate
    Hervás, JG
    Prados, D
    Cerezo, S
    KIDNEY INTERNATIONAL, 2003, 63 : S69 - S72
  • [8] Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients
    Koiwa, F
    Kazama, JJ
    Tokumoto, A
    Onoda, N
    Kato, H
    Okada, T
    Nii-Kono, T
    Fukagawa, M
    Shigematsu, T
    THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 (04) : 336 - 339
  • [9] A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium - Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients
    Chertow, GM
    Dillon, M
    Burke, SK
    Steg, M
    Bleyer, AJ
    Garrett, BN
    Domoto, DT
    Wilkes, BM
    Wombolt, DG
    Slatopolsky, E
    CLINICAL NEPHROLOGY, 1999, 51 (01) : 18 - 26
  • [10] Effects of sevelamer hydrochloride and calcium acetate on acid-base metabolism.
    Pelham, RW
    Gay, SE
    Aronson, BH
    Cleveland, MVB
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 476A - 476A
12345